Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | CNR1 | P21554 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926730 | 0.89 | SMN1; SMN2 (0.76) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL13102351 | 0.87 | CNR1 (0.74) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL30416740 | 0.87 | LMNA (0.73) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL12808473 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL2056328 | 0.87 | CNR1 (0.73) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL22834260 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2CNR1LMNAMAPTEPHX2 | |
| SCHEMBL30415729 | 0.86 | LMNA (1.00) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL25454925 | 0.86 | EPHX2 (0.77) | SMN1; SMN2CNR1LMNAMAPTPOLB | |
| SCHEMBL30416642 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRCNR1LMNAMAPT | |
| SCHEMBL2054619 | 0.86 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRCNR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113831301-B | Benzothiazole derivative and application thereof | 沈阳药科大学 | 2023-06-06 | — | — | CN | claimed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | SMN1; SMN2 3609/4885TSHR 4161/4885CNR1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.